NASDAQ$BCAB
Bioatla Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter and highlighted recent clinical program progress.
BioAtla reported a net loss of $23.2 million for the first quarter ended March 31, 2024, compared to a net loss of $27.5 million for the same quarter in 2023. The company's cash and cash equivalents were $80.6 million as of March 31, 2024, expected to fund operations into the second half of 2025.
- Ozuriftamab vedotin Phase 2 data in SCCHN showed multiple confirmed responses and a manageable safety profile; anticipate FDA meeting for potential registrational trial in 2H 2024.
- Evalstotug Phase 1 study progressing well with initial Phase 2 monotherapy data readout on track for 2Q 2024; anticipate FDA meeting for first-line melanoma potential registrational trial in 2H 2024.
- Mecbotamab vedotin initial 20 patients in Phase 2 UPS study enrolled; anticipate FDA meeting to discuss the remaining trial portion in 2H 2024.
- Cash balance of $80.6 million as of March 31, 2024, is expected to fund operations into 2H 2025.
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$0
Forward guidance
BioAtla anticipates several milestones throughout the remainder of the year, including FDA meetings for potential registrational trials and data readouts from ongoing clinical trials.
Tailwinds
- Anticipate FDA meeting in 2H 2024 for potential registrational trial in SCCHN for ozuriftamab vedotin.
- Expect to clear DLT observation period at 1 gram (14.2 mg/kg) for evalstotug in 2Q 2024.
- Initial Phase 2 monotherapy data readout for evalstotug is on track for 2Q 2024.
- Currently enrolling first-line melanoma and first-line NSCLC patients at 700 mg in combination with pembrolizumab and in combination with pembrolizumab plus chemotherapy, respectively; on track for data readout in 2H 2024
- Anticipate FDA meeting in 2H 2024 for potential registrational trial in first-line, metastatic or unresectable, BRAF-mutated melanoma for evalstotug.
Headwinds
- Potential delays in clinical and pre-clinical trials.
- Uncertainties inherent in research and development.
- Dependence on the success of the CAB technology platform.
- Reliance on third parties for the manufacture and supply of product candidates.
- Potential adverse impacts due to any resurgence of COVID-19 and its variants.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+7.5%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.1% | -15.1% | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro